Unicycive Therapeutics Investors Face November 2 Securities Lawsuit Deadline
Faruqi & Faruqi reminds Unicycive Therapeutics investors of a securities class action lawsuit deadline on November 2, 2026.
Related stories
Mapletree Pan Asia Commercial Trust Q2 Adjusted Revenue SGD 207.483 Million
M impact | EQUITY | Oct 29, 2026, 10:58 PM UTC
Twilio Raises Full-Year Revenue Growth Outlook to 20% After Higher 3Q Profit
Twilio said it now expects full-year revenue growth of 20%, up from its previous outlook of 18% to 18.5%, after reporting higher profit and revenue growth in the third quarter.
M impact | EQUITY | Oct 29, 2026, 10:57 PM UTC
Hanmi Pharmaceutical Licenses Fabry Disease Therapy to BioMarin for $237.5 Million
Hanmi Pharmaceutical licensed its Fabry disease therapy to BioMarin in a deal valued at USD 237.5 million.
M impact | EQUITY | Oct 29, 2026, 10:55 PM UTC
Starbucks says annual profit will exceed expectations as recovery strengthens
Starbucks also reported quarterly same-store sales above expectations. Annual revenue is expected to decline following the sale of its China business.
M impact | EQUITY | Oct 29, 2026, 10:53 PM UTC
TPG Raises Fundraising Target to More Than $55 Billion
TPG raised its full-year fundraising target to more than $55 billion and has roughly $86 billion in uncommitted investment capital, the Wall Street Journal reported.
M impact | EQUITY | Oct 29, 2026, 10:52 PM UTC
Air Canada Cuts Some First-Quarter Capacity on Higher Fuel Costs
Air Canada says it is reducing some capacity in the first quarter as fuel costs rise.
M impact | EQUITY | Oct 29, 2026, 10:52 PM UTC